XML 78 R67.htm IDEA: XBRL DOCUMENT v3.7.0.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Sales	$ 9,434	$ 9,312
Proceeds from sale of marketing rights	50	75
corticotropin marketing rights
Segment Reporting Information [Line Items]
Proceeds from sale of marketing rights		75
Operating Segments
Segment Reporting Information [Line Items]
Sales	9,218	9,009
Operating Segments | Total Pharmaceutical segment sales
Segment Reporting Information [Line Items]
Sales	8,185	8,104
Operating Segments | Total Pharmaceutical segment sales | Zetia
Segment Reporting Information [Line Items]
Sales	334	612
Operating Segments | Total Pharmaceutical segment sales | Vytorin
Segment Reporting Information [Line Items]
Sales	241	277
Operating Segments | Total Pharmaceutical segment sales | Liptruzet
Segment Reporting Information [Line Items]
Sales	49	23
Operating Segments | Total Pharmaceutical segment sales | Adempas
Segment Reporting Information [Line Items]
Sales	84	33
Operating Segments | Total Pharmaceutical segment sales | Januvia
Segment Reporting Information [Line Items]
Sales	839	906
Operating Segments | Total Pharmaceutical segment sales | Janumet
Segment Reporting Information [Line Items]
Sales	496	506
Operating Segments | Total Pharmaceutical segment sales | Implanon/Nexplanon
Segment Reporting Information [Line Items]
Sales	170	134
Operating Segments | Total Pharmaceutical segment sales | NuvaRing
Segment Reporting Information [Line Items]
Sales	160	175
Operating Segments | Total Pharmaceutical segment sales | Follistim AQ
Segment Reporting Information [Line Items]
Sales	81	94
Operating Segments | Total Pharmaceutical segment sales | Zepatier
Segment Reporting Information [Line Items]
Sales	378	50
Operating Segments | Total Pharmaceutical segment sales | Isentress
Segment Reporting Information [Line Items]
Sales	305	340
Operating Segments | Total Pharmaceutical segment sales | Bridion
Segment Reporting Information [Line Items]
Sales	148	90
Operating Segments | Total Pharmaceutical segment sales | Noxafil
Segment Reporting Information [Line Items]
Sales	141	145
Operating Segments | Total Pharmaceutical segment sales | Invanz
Segment Reporting Information [Line Items]
Sales	136	114
Operating Segments | Total Pharmaceutical segment sales | Cancidas
Segment Reporting Information [Line Items]
Sales	121	133
Operating Segments | Total Pharmaceutical segment sales | Cubicin
Segment Reporting Information [Line Items]
Sales	96	292
Operating Segments | Total Pharmaceutical segment sales | Primaxin
Segment Reporting Information [Line Items]
Sales	62	73
Operating Segments | Total Pharmaceutical segment sales | Remicade
Segment Reporting Information [Line Items]
Sales	229	349
Operating Segments | Total Pharmaceutical segment sales | Simponi
Segment Reporting Information [Line Items]
Sales	184	188
Operating Segments | Total Pharmaceutical segment sales | Keytruda
Segment Reporting Information [Line Items]
Sales	584	249
Operating Segments | Total Pharmaceutical segment sales | Emend
Segment Reporting Information [Line Items]
Sales	133	126
Operating Segments | Total Pharmaceutical segment sales | Temodar
Segment Reporting Information [Line Items]
Sales	66	66
Operating Segments | Total Pharmaceutical segment sales | Singulair
Segment Reporting Information [Line Items]
Sales	186	237
Operating Segments | Total Pharmaceutical segment sales | Nasonex
Segment Reporting Information [Line Items]
Sales	139	229
Operating Segments | Total Pharmaceutical segment sales | Dulera
Segment Reporting Information [Line Items]
Sales	82	113
Operating Segments | Total Pharmaceutical segment sales | Cozaar/Hyzaar
Segment Reporting Information [Line Items]
Sales	112	126
Operating Segments | Total Pharmaceutical segment sales | Arcoxia
Segment Reporting Information [Line Items]
Sales	103	111
Operating Segments | Total Pharmaceutical segment sales | Fosamax
Segment Reporting Information [Line Items]
Sales	61	75
Operating Segments | Total Pharmaceutical segment sales | Gardasil/Gardasil 9
Segment Reporting Information [Line Items]
Sales	532	378
Operating Segments | Total Pharmaceutical segment sales | ProQuad/M-M-R II/Varivax
Segment Reporting Information [Line Items]
Sales	355	357
Operating Segments | Total Pharmaceutical segment sales | RotaTeq
Segment Reporting Information [Line Items]
Sales	224	188
Operating Segments | Total Pharmaceutical segment sales | Pneumovax 23
Segment Reporting Information [Line Items]
Sales	163	107
Operating Segments | Total Pharmaceutical segment sales | Zostavax
Segment Reporting Information [Line Items]
Sales	154	125
Operating Segments | Total Pharmaceutical segment sales | Other Pharmaceutical
Segment Reporting Information [Line Items]
Sales	1,037	1,083
Operating Segments | Other segment sales
Segment Reporting Information [Line Items]
Sales	1,033	905
Other
Segment Reporting Information [Line Items]
Sales	$ 216	$ 303

X

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name:	us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_SalesRevenueGoodsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_CorticotropinmarketingrightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_LiptruzetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_IsentressMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_TemodarMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_DuleraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_FosamaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_GardasilMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ZostavaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: